<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>METRONIDAZOLE- metronidazole solution </strong><br>Cardinal Health<br></p></div>
<h1>
<span class="Bold">METRONIDAZOLE Injection USP</span><br><span class="Bold">METRONIDAZOLE</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f8fea355-95f2-4fe3-aeb3-9e9970dab462"></a><a name="section-1"></a><p></p>
<p class="First"><span class="Bold">500 mg/Container (5 mg/mL)</span></p>
<p><span class="Bold">Sterile</span><br><span class="Bold">For Intravenous Infusion Only.</span></p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of Metronidazole Injection USP and other antibacterial drugs, Metronidazole Injection USP should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
</div>
<div class="Warning">
<a name="id_3ca67639-98c0-4158-bf13-64364551ade5"></a><a name="section-2"></a><p></p>
<h1>WARNING</h1>
<p class="First">Metronidazole has been shown to be carcinogenic in mice and rats (see <span class="Bold"><a href="#i4i_precautions_id_e32658df-ef0c-4ddd-ad95-72aef94691fd">PRECAUTIONS</a></span>). Its use, therefore, should be reserved for the conditions described in the <span class="Bold"><a href="#i4i_indications_id_17ee638d-f568-4387-ad2d-e1702197d388">INDICATIONS AND USAGE</a></span> section below.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_e0da1f30-5170-4c42-ac02-9416dfafd704"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Metronidazole Injection USP is a sterile, parenteral dosage form of metronidazole in water.</p>
<p>Each 100 mL of Metronidazole Injection USP contains a sterile, nonpyrogenic, isotonic, buffered solution of Metronidazole USP 500 mg, Sodium Chloride USP 740 mg, Dibasic Sodium Phosphate•7H<span class="Sub">2</span>O USP 112 mg, and Citric Acid Anhydrous USP 40 mg in Water for Injection USP. Metronidazole Injection USP has a calculated osmolarity of 297 mOsmol/liter and a pH of 5.8 (4.5–7.0). Sodium content: 13.5 mEq/container.</p>
<p>Metronidazole is classified as a synthetic antibacterial and antiprotozoal agent and is administered by the intravenous route.</p>
<p>Metronidazole USP is chemically designated 2-methyl-5-nitroimidazole-1-ethanol (C<span class="Sub">6</span>H<span class="Sub">9</span>N<span class="Sub">3</span>O<span class="Sub">3</span>):</p>
<div class="Figure">
<a name="id250"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a7276a00-bb2f-4876-b58b-f2e953d716e4&amp;name=a7276a00-bb2f-4876-b58b-f2e953d716e4-01.jpg">
</div>
<p>Not made with natural rubber latex, PVC, or DEHP. </p>
<p>The PAB® plastic container system is a copolymer of ethylene and propylene formulated and developed for parenteral drugs. The copolymer contains no plasticizers and exhibits virtually no leachability. The safety of the plastic container has been confirmed by biological evaluation procedures.</p>
<p>The material passes Class VI testing as specified in the U.S. Pharmacopeia for Biological Tests–Plastic Containers. These tests have shown that the container is nontoxic and biologically inert. The container-solution unit is a closed system and is not dependent upon entry of external air during administration. No overwrap is necessary.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_64692977-69d6-4c4b-8940-c7a70f7f0c7b"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Metronidazole is a synthetic antibacterial compound. Disposition of metronidazole in the body is similar for both oral and intravenous dosage forms, with an average elimination half-life in healthy humans of eight hours.</p>
<p>The major route of elimination of metronidazole and its metabolites is via the urine (60 to 80% of the dose), with fecal excretion accounting for 6 to 15% of the dose. The metabolites that appear in the urine result primarily from side-chain oxidation (1-[<span class="Italics">β</span>-hydroxyethyl]-2-hydroxymethyl-5-nitroimidazole and 2-methyl-5-nitroimidazole-1-yl-acetic acid) and glucuronide conjugation, with unchanged metronidazole accounting for approximately 20% of the total. Renal clearance of metronidazole is approximately 10 mL/min/1.73 m<span class="Sup">2</span>.</p>
<p>Metronidazole is the major component appearing in the plasma, with lesser quantities of the 2-hydroxymethyl metabolite also being present. Less than 20% of the circulating metronidazole is bound to plasma proteins. Both the parent compound and the metabolite possess <span class="Italics">in vitro</span> bactericidal activity against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of anaerobic bacteria.</p>
<p>Metronidazole appears in cerebrospinal fluid, saliva, and human milk in concentrations similar to those found in plasma. Bactericidal concentrations of metronidazole have also been detected in pus from hepatic <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscesses</span>.</p>
<p>Plasma concentrations of metronidazole are proportional to the administered dose. An eight-hour intravenous infusion of 100 to 4,000 mg of metronidazole in normal subjects showed a linear relationship between dose and peak plasma concentration.</p>
<p>In patients treated with metronidazole injection using a dosage regimen of 15 mg/kg loading dose followed six hours later by 7.5 mg/kg every six hours, peak steady-state plasma concentrations of metronidazole averaged 25 mcg/mL with trough (minimum) concentrations averaging 18 mcg/mL.</p>
<p>Decreased renal function does not alter the single-dose pharmacokinetics of metronidazole. However, plasma clearance of metronidazole is decreased in patients with decreased liver function.</p>
<p>In one study newborn infants appeared to demonstrate diminished capacity to eliminate metronidazole. The elimination half-life, measured during the first three days of life, was inversely related to gestational age. In infants whose gestational ages were between 28 and 40 weeks, the corresponding elimination half-lives ranged from 109 to 22.5 hours.</p>
<div class="Section" data-sectionCode="49489-8">
<a name="i4i_microbiology_id_bad88bb8-de91-4958-9a23-2f09883b5c88"></a><a name="section-3.1"></a><p></p>
<h2>MICROBIOLOGY</h2>
<p class="First">Metronidazole is active <span class="Italics">in vitro</span> against most obligate anaerobes, but does not appear to possess any clinically relevant activity against facultative anaerobes or obligate aerobes. Against susceptible organisms, metronidazole is generally bactericidal at concentrations equal to or slightly higher than the minimal inhibitory concentrations. Metronidazole has been shown to have <span class="Italics">in vitro</span> and clinical activity against the following organisms:</p>
<p>Anaerobic gram-negative bacilli, including:</p>
<p>      <span class="Italics">Bacteroides</span> species, including the <span class="Italics">Bacteroides fragilis</span> group (<span class="Italics">B. fragilis</span>,<span class="Italics"> B. distasonis</span>,<span class="Italics"> B. ovatus, B. thetaiotaomicron</span>,<span class="Italics"> B. vulgatus</span>)</p>
<p>      <span class="Italics">Fusobacterium</span> species</p>
<p>Anaerobic gram-positive bacilli, including:</p>
<p>      <span class="Italics">Clostridium</span> species and susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Eubacterium</span></p>
<p>Anaerobic gram-positive cocci, including:</p>
<p>      <span class="Italics">Peptococcus</span> species</p>
<p>      <span class="Italics">Peptostreptococcus</span> species</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_93d65353-d30c-4ccf-ae08-899d99094c70"></a><a name="section-3.2"></a><p></p>
<h2>SUSCEPTIBILITY TESTS</h2>
<p class="First">Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to metronidazole; however, the rapid, routine susceptibility testing of individual isolates of anaerobic bacteria is not always practical, and therapy may be started while awaiting these results.</p>
<p>Quantitative methods give the most accurate estimates of susceptibility to antibacterial drugs. A standardized agar dilution method and a broth microdilution method are recommended.<span class="Sup">1</span></p>
<p>Control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> are recommended for standardized susceptibility testing. Each time the test is performed, one or more of the following <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> should be included: <span class="Italics">Clostridium perfringens</span> ATCC<span class="Sup">®</span> 13124, <span class="Italics">Bacteroides fragilis</span> ATCC<span class="Sup">®</span> 25285, and <span class="Italics">Bacteroides thetaiotaomicron</span> ATCC<span class="Sup">®</span> 29741. The mode metronidazole MICs for those three <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> are reported to be 0.25, 0.25 and 0.5 mcg/mL, respectively.</p>
<p>A clinical laboratory test is considered under acceptable control if the results of the control <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> are within one doubling dilution of the mode MICs reported for metronidazole.</p>
<p>A bacterial isolate may be considered susceptible if the MIC value for metronidazole is not more than 16 mcg/mL. An organism is considered "resistant" if the MIC is greater than 16 mcg/mL. A report of "resistant" from the laboratory indicates that the infecting organism is not likely to respond to therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_17ee638d-f568-4387-ad2d-e1702197d388"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of Metronidazole Injection USP and other antibacterial drugs, Metronidazole Injection USP should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d6a28ec4-29d2-40dc-881b-e7c28bc65ef5"></a><a name="section-4.1"></a><p></p>
<h2>TREATMENT OF ANAEROBIC <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span></h2>
<p class="First">Metronidazole Injection USP is indicated in the treatment of serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with Metronidazole Injection USP therapy. In a mixed aerobic and anaerobic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, antibiotics appropriate for the treatment of the aerobic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> should be used in addition to Metronidazole Injection USP.</p>
<p>Metronidazole Injection USP is effective in <span class="Italics">Bacteroides fragilis</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> resistant to clindamycin, chloramphenicol, and penicillin.</p>
<p><span class="Bold"><span class="Italics">Intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">Abdominal Infections</span></span></span>, including <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span>, intra-<span class="product-label-link" type="condition" conceptid="4326255" conceptname="Abdominal abscess">abdominal abscess</span>, and <span class="product-label-link" type="condition" conceptid="201901" conceptname="Abscess of liver">liver abscess</span>, caused by <span class="Italics">Bacteroides</span> species including the <span class="Italics">B. fragilis</span> group (<span class="Italics">B. fragilis</span>, <span class="Italics">B. distasonis</span>, <span class="Italics">B. ovatus</span>, <span class="Italics">B. thetaiotaomicron</span>, <span class="Italics">B. vulgatus</span>), <span class="Italics">Clostridium</span> species, <span class="Italics">Eubacterium</span> species, <span class="Italics">Peptococcus</span> species, and <span class="Italics">Peptostreptococcus</span> species.</p>
<p><span class="Bold"><span class="Italics">Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></span> caused by <span class="Italics">Bacteroides</span> species including the <span class="Italics">B. fragilis</span> group, <span class="Italics">Clostridium</span> species, <span class="Italics">Peptococcus </span>species, <span class="Italics">Peptostreptococcus</span> species, and <span class="Italics">Fusobacterium</span> species.</p>
<p><span class="Bold"><span class="Italics">Gynecologic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></span>, including <span class="product-label-link" type="condition" conceptid="4302765" conceptname="Endometritis">endometritis</span>, endomyometritis, tubo-ovarian <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>, and post-surgical vaginal cuff <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, caused by <span class="Italics">Bacteroides</span> species including the <span class="Italics">B. fragilis</span> group, <span class="Italics">Clostridium</span> species, <span class="Italics">Peptococcus </span>species, and <span class="Italics">Peptostreptococcus</span> species.</p>
<p><span class="Bold"><span class="Italics">Bacterial <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Septicemia</span></span></span> caused by <span class="Italics">Bacteroides</span> species including the <span class="Italics">B. fragilis</span> group and <span class="Italics">Clostridium</span> species.</p>
<p><span class="Bold"><span class="Italics">Bone and <span class="product-label-link" type="condition" conceptid="4180167" conceptname="Infectious disorder of joint">Joint Infections</span></span></span>, as adjunctive therapy, caused by <span class="Italics">Bacteroides</span> species including the <span class="Italics">B. fragilis</span> group.</p>
<p><span class="Bold"><span class="Italics">Central Nervous System (CNS) <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></span></span>, including <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span> and <span class="product-label-link" type="condition" conceptid="435509" conceptname="Intracranial abscess">brain abscess</span>, caused by <span class="Italics">Bacteroides</span> species including the <span class="Italics">B. fragilis</span> group.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">Lower Respiratory Tract Infections</span></span></span>, including <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="4209859" conceptname="Empyema">empyema</span>, and <span class="product-label-link" type="condition" conceptid="257010" conceptname="Abscess of lung">lung abscess</span>, caused by <span class="Italics">Bacteroides</span> species including the <span class="Italics">B. fragilis</span> group.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="441589" conceptname="Endocarditis">Endocarditis</span></span></span> caused by <span class="Italics">Bacteroides</span> species including the <span class="Italics">B. fragilis</span> group.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_28b95777-0e6b-4df1-95c0-04ef7e6105b3"></a><a name="section-4.2"></a><p></p>
<h2>PROPHYLAXIS</h2>
<p class="First">The <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> administration of Metronidazole Injection USP preoperatively, intraoperatively, and postoperatively may reduce the incidence of <span class="product-label-link" type="condition" conceptid="437474" conceptname="Postoperative infection">postoperative infection</span> in patients undergoing elective colorectal surgery which is classified as contaminated or potentially contaminated.</p>
<p><span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> use of Metronidazole Injection USP should be discontinued within 12 hours after surgery. If there are signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, specimens for cultures should be obtained for the identification of the causative organism(s) so that appropriate therapy may be given (see <span class="Bold"><a href="#i4i_dosage_admin_id_6b63cccb-ed40-4d4f-862f-329089948361">DOSAGE AND ADMINISTRATION</a></span>).</p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole and other antibacterial drugs, metronidazole should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antimicrobial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_0b774819-de17-4ac8-b7fa-087095d07a7d"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Metronidazole Injection USP is contraindicated in patients with a prior history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to metronidazole or other nitroimidazole derivatives.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_90d62504-9f25-4f6e-a97a-f35d257badd6"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f176c4d0-33d1-468e-b6f9-3f8787acd09f"></a><a name="section-6.1"></a><p></p>
<h2>CENTRAL AND PERIPHERAL NERVOUS SYSTEM EFFECTS</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsive seizures</span>, <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span>, optic and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, the latter characterized mainly by <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> or <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> of an extremity, have been reported in patients treated with metronidazole. The appearance of abnormal neurologic signs demands the prompt evaluation of the benefit/risk ratio of the continuation of therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_e32658df-ef0c-4ddd-ad95-72aef94691fd"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_7e0fc011-fbbb-4a0c-9e57-3e107e4add4b"></a><a name="section-7.1"></a><p></p>
<h2>GENERAL</h2>
<p class="First">Patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> metabolize metronidazole slowly, with resultant accumulation of metronidazole and its metabolites in the plasma. Accordingly, for such patients, doses below those usually recommended should be administered cautiously.</p>
<p>Administration of solutions containing sodium ions may result in <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">sodium retention</span>. Care should be taken when administering Metronidazole Injection USP to patients receiving corticosteroids or to patients predisposed to <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>.</p>
<p>Known or previously unrecognized <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">candidiasis</span> may present more prominent symptoms during therapy with Metronidazole Injection USP and requires treatment with a candicidal agent.</p>
<p>Prescribing Metronidazole Injection USP in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_8719bd43-fde6-4eaa-89c5-c215cafa65f9"></a><a name="section-7.2"></a><p></p>
<h2>INFORMATION FOR PATIENTS</h2>
<p class="First">Patients should be counseled that antibacterial drugs including Metronidazole Injection USP should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (<span class="Italics">e.g.,</span> the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When Metronidazole Injection USP is prescribed to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Metronidazole Injection USP or other antibacterial drugs in the future.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_51b7529d-6b19-4a6f-8042-a1f29aee6cf7"></a><a name="section-7.3"></a><p></p>
<h2>LABORATORY TESTS</h2>
<p class="First">Metronidazole is a nitroimidazole, and Metronidazole Injection USP should be used with caution in patients with evidence of or history of <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasia</span>. A mild <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> has been observed during its administration; however, no persistent hematologic abnormalities attributable to metronidazole have been observed in clinical studies. Total and differential leukocyte counts are recommended before and after therapy.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_80474dd9-9c26-493e-acaf-28b6e8c3c2f0"></a><a name="section-7.4"></a><p></p>
<h2>DRUG INTERACTIONS</h2>
<p class="First">Metronidazole has been reported to potentiate the anticoagulant effect of warfarin and other oral coumarin anticoagulants, resulting in a prolongation of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time. This possible drug interaction should be considered when Metronidazole Injection USP is prescribed for patients on this type of anticoagulant therapy.</p>
<p>The simultaneous administration of drugs that induce microsomal liver enzymes, such as phenytoin or phenobarbital, may accelerate the elimination of metronidazole, resulting in reduced plasma levels; impaired clearance of phenytoin has also been reported.</p>
<p>The simultaneous administration of drugs that decrease microsomal liver enzyme activity, such as cimetidine, may prolong the half-life and decrease plasma clearance of metronidazole.</p>
<p>Alcoholic beverages should not be consumed during metronidazole therapy because <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, and <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> may occur.</p>
<p><span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychotic reactions</span> have been reported in alcoholic patients who are using metronidazole and disulfiram concurrently. Metronidazole should not be given to patients who have taken disulfiram within the last two weeks.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="i4i_drug_lab_interaction_id_996c1c20-a4f6-4fa2-a199-ec0b41f1e919"></a><a name="section-7.5"></a><p></p>
<h2>DRUG/LABORATORY TEST INTERACTIONS</h2>
<p class="First">Metronidazole may interfere with certain types of determinations of serum chemistry values, such as <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> (AST, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>), <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> (ALT, SGPT), lactate dehydrogenase (LDH), triglycerides, and hexokinase glucose. Values of zero may be observed. All of the assays in which interference has been reported involve enzymatic coupling of the assay to oxidation-reduction of nicotinamide adenine dinucleotide (NAD<span class="Sup">+</span><a name="id499"></a><img alt="symbol" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a7276a00-bb2f-4876-b58b-f2e953d716e4&amp;name=a7276a00-bb2f-4876-b58b-f2e953d716e4-02.jpg"> NADH). Interference is due to the similarity in absorbance peaks of NADH (340 nm) and metronidazole (322 nm) at pH 7.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_b9d19981-0fbc-4a30-b51e-593a70abd105"></a><a name="section-7.6"></a><p></p>
<h2>CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7bb9c29e-f342-48e0-b668-5118807641a3"></a><a name="section-7.6.1"></a><p></p>
<h3><span class="Bold">Tumorigenicity in Rodents</span></h3>
<p class="First">Metronidazole has shown evidence of carcinogenic activity in studies involving chronic, oral administration in mice and rats, but similar studies in the hamster gave negative results. Also, metronidazole has shown mutagenic activity in a number of <span class="Italics">in vitro</span> assay systems, but studies in mammals (<span class="Italics">in vivo</span>) failed to demonstrate a potential for genetic damage.</p>
</div>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_541dcb20-a8e3-4686-90a5-77f048d6d54b"></a><a name="section-7.7"></a><p></p>
<h2>PREGNANCY</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_bb1ce3bf-09ec-427f-8d4d-726ff6303ddc"></a><a name="section-7.7.1"></a><p></p>
<h3><span class="Bold">Teratogenic Effects-Pregnancy Category B</span></h3>
<p class="First">Metronidazole crosses the placental barrier and enters the fetal circulation rapidly. Reproduction studies have been performed in rats at doses up to five times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to metronidazole. Metronidazole administered intraperitoneally to pregnant mice at approximately the human dose caused fetotoxicity; administered orally to pregnant mice, no fetotoxicity was observed. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, and because metronidazole is a carcinogen in rodents, this drug should be used during pregnancy only if clearly needed (see <span class="Bold"><a href="#i4i_contraindications_id_0b774819-de17-4ac8-b7fa-087095d07a7d">CONTRAINDICATIONS</a></span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_c5792b22-cd86-45a7-86f5-d228c6b15d1e"></a><a name="section-7.8"></a><p></p>
<h2>NURSING MOTHERS</h2>
<p class="First">Metronidazole is secreted in human milk in concentrations similar to those found in plasma. Because of the potential for tumorigenicity shown for metronidazole in mouse and rat studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_230abf94-6953-4f88-9755-5315f497412d"></a><a name="section-7.9"></a><p></p>
<h2>PEDIATRIC USE</h2>
<p class="First">Safety and effectiveness in children have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_402f6ed6-f86c-411c-af1b-bbbb45374758"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The most serious adverse reactions reported in patients treated with metronidazole injection have been <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive seizures</span>, <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span>, optic and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, the latter characterized mainly by <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> or <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> of an extremity. Since persistent <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> has been reported in some patients receiving prolonged oral administration of metronidazole, patients should be observed carefully if <span class="product-label-link" type="condition" conceptid="4204047" conceptname="Neurological symptom">neurologic symptoms</span> occur and a prompt evaluation made of the benefit/risk ratio of the continuation of therapy.</p>
<p>The following reactions have also been reported during treatment with metronidazole injection:</p>
<p><span class="Bold"><span class="Italics">GASTROINTESTINAL:</span></span> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and an unpleasant metallic taste.</p>
<p><span class="Bold"><span class="Italics">HEMATOPOIETIC:</span></span> Reversible <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (<span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>).</p>
<p><span class="Bold"><span class="Italics">DERMATOLOGIC:</span></span> Erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.</p>
<p><span class="Bold"><span class="Italics">CENTRAL NERVOUS SYSTEM:</span></span> <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">Encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive seizures</span>, <span class="product-label-link" type="condition" conceptid="380410" conceptname="Nutritional optic neuropathy">optic neuropathy</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>.</p>
<p><span class="Bold"><span class="Italics">LOCAL REACTIONS:</span></span> <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">Thrombophlebitis</span> after intravenous infusion. This reaction can be minimized or avoided by avoiding prolonged use of indwelling intravenous catheters.</p>
<p><span class="Bold"><span class="Italics">OTHER:</span></span> <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>. Instances of a darkened urine have also been reported, and this manifestation has been the subject of a special investigation. Although the pigment which is probably responsible for this phenomenon has not been positively identified, it is almost certainly a metabolite of metronidazole and seems to have no clinical significance.</p>
<p>The following adverse reactions have been reported during treatment with oral metronidazole:</p>
<p><span class="Bold"><span class="Italics">GASTROINTESTINAL:</span></span> <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, sometimes accompanied by <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, and occasionally <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">epigastric distress</span>, abdominal cramping, and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>.</p>
<p><span class="Bold"><span class="Italics">MOUTH:</span></span> A sharp, unpleasant metallic taste is not unusual. Furry tongue, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, and <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span> have occurred; these may be associated with a sudden overgrowth of <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> which may occur during effective therapy.</p>
<p><span class="Bold"><span class="Italics">HEMATOPOIETIC:</span></span> Reversible <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (<span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>); rarely, reversible <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p><span class="Bold"><span class="Italics">CARDIOVASCULAR:</span></span> Flattening of the T-wave may be seen in electrocardiographic tracings.</p>
<p><span class="Bold"><span class="Italics">CENTRAL NERVOUS SYSTEM:</span></span> <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">Encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="438418" conceptname="Non-pyogenic meningitis">aseptic meningitis</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive seizures</span>, <span class="product-label-link" type="condition" conceptid="380410" conceptname="Nutritional optic neuropathy">optic neuropathy</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY</span>:</span></span> <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>, erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, dryness of mouth (or vagina or vulva), and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>.</p>
<p><span class="Bold"><span class="Italics">RENAL:</span></span> <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">Dysuria</span>, <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">incontinence</span>, a sense of pelvic pressure, and darkened urine.</p>
<p><span class="Bold"><span class="Italics">OTHER:</span></span> <span class="product-label-link" type="condition" conceptid="194475" conceptname="Hiccoughs">Hiccup</span>. Proliferation of <span class="Italics"><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candida</span></span> in the vagina, <span class="product-label-link" type="condition" conceptid="439080" conceptname="Dyspareunia">dyspareunia</span>, decrease of libido, <span class="product-label-link" type="condition" conceptid="4215578" conceptname="Proctitis">proctitis</span>, and fleeting <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pains</span> sometimes resembling "<span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">serum sickness</span>". If patients receiving metronidazole drink alcoholic beverages, they may experience <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal distress</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, or <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. A modification of the taste of alcoholic beverages has also been reported.</p>
<p>Crohn's disease patients are known to have an increased incidence of gastrointestinal and certain extraintestinal cancers. There have been some reports in the medical literature of breast and colon cancer in Crohn's disease patients who have been treated with metronidazole at high doses for extended periods of time. A cause and effect relationship has not been established. Crohn's disease is not an approved indication for Metronidazole Injection USP.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_d8ea4b45-1044-4ffb-b4cc-d371b6303756"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">The use of dosages of metronidazole higher than those recommended has been reported. These include the use of 27 mg/kg three times a day for 20 days, and the use of 75 mg/kg as a single loading dose followed by 7.5 mg/kg maintenance doses. No adverse reactions were reported in either of the two cases.</p>
<p>Single oral doses of metronidazole, up to 15 g, have been reported in <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempts</span> and accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span>. Symptoms reported include <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>.</p>
<p>Oral metronidazole has been studied as a radiation sensitizer in the treatment of <span class="product-label-link" type="condition" conceptid="197506" conceptname="Malignant neoplasm of abdomen">malignant tumors</span>. Neurotoxic effects, including <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span>, have been reported after 5 to 7 days of doses of 6 to 10.4 g every other day.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4702984c-7321-4a0b-8352-ec0b4258f42f"></a><a name="section-9.1"></a><p></p>
<h2>TREATMENT</h2>
<p class="First">There is no specific antidote for <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>; therefore, management of the patient should consist of symptomatic and supportive therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_6b63cccb-ed40-4d4f-862f-329089948361"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">In elderly patients the pharmacokinetics of metronidazole may be altered and therefore monitoring of serum levels may be necessary to adjust the metronidazole dosage accordingly.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_11ba3c1e-2450-47b4-a9e9-6ef8e3aabc57"></a><a name="section-10.1"></a><p></p>
<h2>TREATMENT OF ANAEROBIC <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span></h2>
<p class="First">The recommended dosage schedule for <span class="Bold">Adults</span> is:</p>
<table width="100%">
<col width="50%">
<col width="50%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule"><p class="First">Loading Dose</p></td>
<td class="Toprule"><p class="First">15 mg/kg infused over one hour (approximately 1 g for a 70-kg adult).</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First">Maintenance Dose</p></td>
<td class="Botrule"><p class="First">7.5 mg/kg infused over one hour every six hours (approximately 500 mg for a 70-kg adult). The first maintenance dose should be instituted six hours following the initiation of the loading dose.</p></td>
</tr>
</tbody>
</table>
<p>Patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span> metabolize metronidazole slowly, with resultant accumulation of metronidazole and its metabolites in the plasma. Accordingly, for such patients, doses below those usually recommended should be administered cautiously. Close monitoring of plasma metronidazole levels and toxicity is recommended.<span class="Sup">2</span></p>
<p>In patients receiving metronidazole injection in whom gastric secretions are continuously removed by nasogastric <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span>, sufficient metronidazole may be removed in the aspirate to cause a reduction in serum levels.</p>
<p>The dose of Metronidazole Injection USP should not be specifically reduced in anuric patients since accumulated metabolites may be rapidly removed by dialysis.</p>
<p>The usual duration of therapy is 7 to 10 days; however, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the bone and joint, lower respiratory tract, and endocardium may require longer treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b033180f-5ace-46ae-87cb-9447a2d1a764"></a><a name="section-10.2"></a><p></p>
<h2>PROPHYLAXIS</h2>
<p class="First">For surgical <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> use, to prevent <span class="product-label-link" type="condition" conceptid="437474" conceptname="Postoperative infection">postoperative infection</span> in contaminated or potentially contaminated colorectal surgery, the recommended dosage schedule for adults is:</p>
<dl>
<dt>1.</dt>
<dd>15 mg/kg infused over 30 to 60 minutes and completed approximately one hour before surgery, followed by:</dd>
<dt>2.</dt>
<dd>7.5 mg/kg infused over 30 to 60 minutes at 6 and 12 hours after the initial dose.</dd>
</dl>
<p>It is important that (1) administration of the initial preoperative dose be completed approximately one hour before surgery so that adequate drug levels are present in the serum and tissues at the time of initial incision, and (2) Metronidazole Injection USP be administered, if necessary, at 6-hour intervals to maintain effective drug levels. <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> use of Metronidazole Injection USP should be limited to the day of surgery only, following the above guidelines.</p>
<p>Parenteral therapy may be changed to oral metronidazole when conditions warrant, based upon the severity of the disease and the response of the patient to treatment with Metronidazole Injection USP. The usual adult oral dosage is 7.5 mg/kg every six hours.</p>
<p>A maximum of 4 g should not be exceeded during a 24-hour period.</p>
<p><span class="Bold">CAUTION: Metronidazole Injection USP is to be administered by slow intravenous drip infusion only, either as a continuous or intermittent infusion. IV admixtures containing metronidazole and other drugs should be avoided. Additives should not be introduced into this solution. If used with a primary intravenous fluid system, the primary solution should be discontinued during metronidazole infusion. DO NOT USE EQUIPMENT CONTAINING ALUMINUM (E.G., NEEDLES, CANNULAE) THAT WOULD COME IN CONTACT WITH THE DRUG SOLUTION.</span></p>
<p>Metronidazole Injection USP is a ready-to-use isotonic solution. <span class="Bold">NO DILUTION OR BUFFERING IS REQUIRED. </span>Do not refrigerate. Each container of Metronidazole Injection USP contains 13.5 mEq of sodium.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if cloudy or precipitated or if the seals are not intact.</p>
<p>Use sterile equipment. It is recommended that the intravenous administration apparatus be replaced at least once every 24 hours.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_f929b6ae-4b98-44a8-963c-c24c31fe7bd1"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Metronidazole Injection USP, sterile, is supplied in 100 mL PAB® plastic containers, each containing an isotonic, buffered solution of 500 mg metronidazole; individually packaged in boxes of 24.</p>
<table width="100%">
<col width="33%">
<col width="33%">
<col width="33%">
<thead><tr class="First Last">
<th class="Botrule Rrule Toprule" align="center" valign="bottom"><span class="Bold">NDC</span></th>
<th class="Botrule Rrule Toprule" align="center" valign="bottom"><span class="Bold">REF</span></th>
<th class="Botrule Lrule Toprule" align="center" valign="bottom"><span class="Bold">Size</span></th>
</tr></thead>
<tbody><tr class="First Last">
<td class="Botrule Toprule" align="center" valign="bottom"><p class="First"> Metronidazole Injection USP<br>0264-5535-32</p></td>
<td class="Botrule Toprule" align="center" valign="bottom"><p class="First"> D5353-5224</p></td>
<td class="Botrule Toprule" align="center" valign="bottom"><p class="First"> 100 mL</p></td>
</tr></tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_47973159-9783-4345-9627-2f0bf78a32db"></a><a name="section-11.1"></a><p></p>
<p class="First">Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. Protect from freezing. It is recommended that the product be stored at room temperature (25°C); however, brief exposure up to 40°C does not adversely affect the product.</p>
<p><span class="Bold">Protect from light until use.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_febda6c5-74d6-4a02-837e-81d2c4c4e144"></a><a name="section-12"></a><p></p>
<p class="First"><span class="Bold">Rx only</span></p>
<p>Revised: May 2013</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_90f5a4f1-aeb1-43b6-8f79-aaca672cbe31"></a><a name="section-13"></a><p></p>
<h1>REFERENCES</h1>
<dl>
<dt>1.</dt>
<dd>M11-A6 – Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard – Sixth Edition, National Committee for Clinical Laboratory Standards, and Sutter, <span class="Italics">et al</span>.: Collaborative Evaluation of a Proposed Reference Dilution Method of Susceptibility Testing of Anaerobic Bacteria. Antimicrob. Agents Chemother. 16:495–502 (Oct.) 1979; and Tally, <span class="Italics">et al.</span>: <span class="Italics">In Vitro</span> Activity of Thienamycin, Antimicrob. Agents Chemother. 14:436–438 (Sept.) 1978. </dd>
<dt>2.</dt>
<dd>Ralph ED, Kirby WMM: Bioassay of Metronidazole With Either Anaerobic or Aerobic Incubation, J. Infect. Dis. 132:587–591 (Nov.) 1975, or Gulaid, <span class="Italics">et al</span>: Determination of Metronidazole and its Major Metabolites in Biological Fluids by High Pressure Liquid Chromatography, Br. J. Clin. Pharmacol. 6:430–432, 1978.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_465f6c7a-6852-4918-9125-2252c400b2ed"></a><a name="section-14"></a><p></p>
<p class="First">PAB is a registered trademark of B. Braun Medical Inc.</p>
<p>ATCC is a registered trademark of the American Type Culture Collection.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9f708ada-1a83-4340-bb59-d2c6a093aabc"></a><a name="section-15"></a><p></p>
<h1>Directions for Use of PAB® Plastic Container System</h1>
<p class="First"><span class="Bold">CAUTION: DO NOT ADMIX WITH OTHER DRUGS.</span></p>
<p>MUST NOT BE USED IN SERIES CONNECTIONS.</p>
<p><span class="Bold">For intravenous infusion only.</span></p>
<p>Store the individual container in the storage carton until ready to use.</p>
<p>Aseptic technique is required.</p>
<p><span class="Bold">Caution</span> – Before use, perform the following checks: <br><br>Read the label. Ensure solution is the one ordered and is within the expiration date. <br><br>Inspect the solution in good light for cloudiness, haze or particulate matter; check the container for leakage or damage. Any container which is suspect should not be used.<br><br>Use only if solution is clear and container and seals are intact.<br><br>Single dose plastic container. Discard unused portion.<br><br>Consult Package Insert for complete product information. </p>
<dl>
<dt>1.</dt>
<dd>
<span class="Bold">Identify Set Port (See Figure A).</span><br><br><div class="Figure">
<a name="id790"></a><img alt="Figure A illustration" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a7276a00-bb2f-4876-b58b-f2e953d716e4&amp;name=a7276a00-bb2f-4876-b58b-f2e953d716e4-03.jpg">
</div>
<br>
</dd>
<dt>2.</dt>
<dd>
<span class="Bold">Caution</span> – IV admixtures containing metronidazole and other drugs should be avoided. Additives should not be introduced into the Metronidazole Injection USP solution. If used with a primary intravenous fluid system, the primary solution should be discontinued during metronidazole infusion. Do not use equipment containing aluminum (<span class="Italics">e.g.,</span> needles, cannulae, etc.) that may contact the drug solution. </dd>
<dt>3.</dt>
<dd>
<span class="Bold">To Attach Administration Set</span><br>To aseptically remove the set port closure: hold container below the set port and grasp the foil tab between the thumb and forefinger then pull the tab in two steps shown in <span class="Bold">Figure B Steps 1 and 2</span>. <br><br><div class="Figure">
<a name="id802"></a><img alt="Figure B illustration" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a7276a00-bb2f-4876-b58b-f2e953d716e4&amp;name=a7276a00-bb2f-4876-b58b-f2e953d716e4-04.jpg">
</div>
<br>
</dd>
<dt>4.</dt>
<dd>Push spike through the diaphragm of the port <span class="Bold">(See Figure C)</span>. Hang container using hole on the lower flap. Prime set in accordance with the <span class="Bold">Directions for Use</span> provided with the set in use.<br><br><div class="Figure">
<a name="id809"></a><img alt="Figure C illustration" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a7276a00-bb2f-4876-b58b-f2e953d716e4&amp;name=a7276a00-bb2f-4876-b58b-f2e953d716e4-05.jpg">
</div>
</dd>
</dl>
<p>PAB containers can be safely transported in a standard 6-inch carrier through a pneumatic tube system that is well maintained and running properly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_54c95b1c-4481-412a-9c66-dc1485c43c03"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">B. Braun Medical Inc.</span><br>Irvine, CA 92614-5895 USA<br>1-800-227-2862<br>www.bbraun.com<br>Made in USA</p>
<p>Y36-002-840  LD-438-1</p>
<p>Repackaged by Cardinal Health</p>
<p>Zanesville, OH 43701</p>
<p>IA6624</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_bdbde073-f243-4bb8-9490-393f145fc830"></a><a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 100 mL Bag</h1>
<p class="First"><span class="Bold">Metronidazole Injection USP</span></p>
<p><span class="Bold">500 mg/ Container (5 mg/mL)</span></p>
<p>1 x 100 mL PAB CONTAINERS</p>
<div class="Figure">
<a name="id588813272"></a><img alt="bag label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a7276a00-bb2f-4876-b58b-f2e953d716e4&amp;name=image-01.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>METRONIDAZOLE 		
					</strong><br><span class="contentTableReg">metronidazole solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55154-5175(NDC:0264-5535)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>METRONIDAZOLE</strong> (METRONIDAZOLE) </td>
<td class="formItem">METRONIDAZOLE</td>
<td class="formItem">500 mg  in 100 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">740 mg  in 100 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM PHOSPHATE, DIBASIC</strong></td>
<td class="formItem">112 mg  in 100 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ANHYDROUS CITRIC ACID</strong></td>
<td class="formItem">40 mg  in 100 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55154-5175-8</td>
<td class="formItem">1  in 1 BAG</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">100 mL in 1 CONTAINER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA018900</td>
<td class="formItem">09/29/1983</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Cardinal Health
							(188557102)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Cardinal Health</td>
<td class="formItem"></td>
<td class="formItem">188557102</td>
<td class="formItem">REPACK(55154-5175)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f4236679-d8b0-4c9d-a392-41178d19455b</div>
<div>Set id: a7276a00-bb2f-4876-b58b-f2e953d716e4</div>
<div>Version: 3</div>
<div>Effective Time: 20140812</div>
</div>
</div> <div class="DistributorName">Cardinal Health</div></p>
</body></html>
